Biotechnology

As Prime Medicine prepares for a key investor conference, its next-gen 'search and replace' gene editing technology faces a crucial test. Can it deliver on its promise?

With a potential $4 billion on the line, CytomX and Regeneron are building a new class of cancer therapies designed to act like autonomous agents in the body.

Nirrin Technologies launches TALOS™, a system using novel laser spectroscopy to eliminate dilution and variability, promising a new standard for biomanufacturing.

New long-term data for UPLIZNA and TAVNEOS show sustained disease control and reduced steroid use, offering a tangible difference for rare disease patients.

Insulet's latest Omnipod 5 enhancements are more than a software update; they're a strategic move in the diabetes tech race. Here's what it means.

A parent-founded nonprofit is funding a landmark gene therapy trial, aiming to create the first-ever treatment for a rare neurodevelopmental disorder.

Perspective Therapeutics is testing a potent alpha-particle therapy for meningioma, the most common brain tumor, offering a new option where surgery fails.

At a Vancouver gala, Neighbourhood Pharmacies didn't just give out awards; it signaled a strategic shift. Meet the leaders pushing pharmacies into a new era.

MiniMed and Abbott are partnering on a dual glucose-ketone sensor, a move that could shift diabetes care from crisis management to proactive DKA prevention.

As the world grapples with drug-resistant bacteria, an Israeli biotech is testing a novel drug that physically destroys pathogens. Can it turn the tide?

Finland's capital is inviting firms to its '90 Hour Helsinki' program, offering a fast-track to top R&D clusters without the heavy upfront investment.

A recent FDA approval for a generic cancer drug adds to a growing market, revealing the strategic alliances redefining healthcare access.

New data on Syndax Pharma's Revuforj shows a 90% survival rate in a high-risk leukemia group, signaling a potential paradigm shift and major market catalyst.

Amidst a national pollinator crisis, a Colorado development shows how intentional design can reverse decline, offering a powerful model for urban ecology.

As Capital Edge marks 16 years by reaffirming its niche focus, we explore the explosive growth of specialized consulting driven by byzantine federal rules.

A call for research on vaccine side effects exposes a deeper crisis: the collapse of public trust in science. Can rigorous data heal a polarized nation?

Bluejay Diagnostics secures critical funding to advance its rapid sepsis test, extending its cash runway but raising questions about shareholder dilution.

Stonegate Capital's updated coverage validates AB Science's pivot to ALS and AML, but can its promising clinical assets and shrewd financing de-risk the path forward?

A two-year delay for Carbios' biorecycling plant in China isn't a failure, but a harsh lesson in scaling innovation. Here's what it means for the future.

NexTel Medical acquires two telehealth firms for an instant $135K in monthly revenue, aiming to launch its Maxasome™ exosome therapies to 1,850 clinics.